Consultation record

Submissions accepted in part — page 5

Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.

Submissions

377 documents · page 5 of 13

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-MELANOCORTIN/010	Draft scoping review: melanocortin receptor agonists	Dr Liesbeth Achterberg	Patient-reported outcomes are collected by the trials and not reported by the review
DRAFT-MELANOCORTIN/001	Draft scoping review: melanocortin receptor agonists	Dr Ngozi Zetterlund	The choice of effect measure is not justified and changes the appearance of the result
DRAFT-MELANOCORTIN/002	Draft scoping review: melanocortin receptor agonists	Kolawole Jankowiak-Osei	References should carry a persistent identifier for every cited source
DRAFT-MELANOCORTIN/003	Draft scoping review: melanocortin receptor agonists	Dr Nadezhda Lavrentiev	Statistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-SEARCH-STRAT/005	Draft search-strategy template for the synthesis series	Dr Quintus Rautavaara	References should carry a persistent identifier for every cited source
DRAFT-SEARCH-STRAT/007	Draft search-strategy template for the synthesis series	Dr Liesbeth Delacroix-Njoku	The document is unreadable without specialist training
DRAFT-SEARCH-STRAT/002	Draft search-strategy template for the synthesis series	Dr Liesbeth Zaleski-Mbeki	Automated assistance in screening should be disclosed and validated
DRAFT-SEARCH-STRAT/017	Draft search-strategy template for the synthesis series	Dr Oisín Rautavaara	The database set omits sources relevant to the compounds in scope
DRAFT-PRINT-AND-AR/014	Draft print and archival format for Institute documents	Dr Oisín Marchetti-Bassey	The threshold between a correction and a new version is drawn too high
DRAFT-PRINT-AND-AR/005	Draft print and archival format for Institute documents	Dr Séverine Oduya-Kaltenbrunner	The secretariat answers submissions and is not itself named
DRAFT-PRINT-AND-AR/011	Draft print and archival format for Institute documents	Ignatius Erlingsson	References should carry a persistent identifier for every cited source
DRAFT-PRINT-AND-AR/006	Draft print and archival format for Institute documents	Dr Liesbeth Achterberg	A party criticised in an assessment should have a right of reply
DRAFT-PRINT-AND-AR/008	Draft print and archival format for Institute documents	Dr Quentin Enthoven	The document is unreadable without specialist training
DRAFT-CERTAINTY-IN/002	Draft certainty index	Dr Matthias Whitmarsh-Obi	References should carry a persistent identifier for every cited source
DRAFT-CERTAINTY-IN/006	Draft certainty index	Dr Hamish Nyquist-Obiora	The front matter delays the reader from reaching the assessment
DRAFT-CERTAINTY-IN/014	Draft certainty index	Dr Lorcan Trelawney	The anchor outcome for an indication is not the outcome a decision turns on
DRAFT-CERTAINTY-IN/005	Draft certainty index	Dr Marisol Dunmore-Ekpo	An index organised by certainty invites comparison between ratings that are not comparable
DRAFT-CERTAINTY-IN/013	Draft certainty index	Dr Séverin Oppenheimer-Ade	A surrogate anchor should not be permitted at all
DRAFT-AMYCRETIN-MO/005	Draft monograph: amycretin	Dr Theodora Ximenes	Point estimates are given without an interval
DRAFT-AMYCRETIN-MO/013	Draft monograph: amycretin	Dr Sigrún Lavrentiev	The preclinical section is extensive and the clinical section is not
DRAFT-AMYCRETIN-MO/014	Draft monograph: amycretin	Radoslava Palmgren-Kofi industry	The monograph should reproduce the approved labelling rather than paraphrase it
DRAFT-AMYCRETIN-MO/007	Draft monograph: amycretin	Dr Valentin Castellanos-Reid	Anti-drug antibody data are omitted
DRAFT-5-AMINO-1MQ-/004	Draft monograph: 5-amino-1MQ	Dr Zebedee Zaleski-Mbeki	The analytical section is longer than the clinical assessment it accompanies
DRAFT-5-AMINO-1MQ-/003	Draft monograph: 5-amino-1MQ	Dr Ottoline Fitzgerald-Nwosu	The recorded evidence gaps omit outcomes a reader would consider material
DRAFT-AOD-9604-MON/001	Draft monograph: AOD-9604	Dr Lorcan Uttridge	Point estimates are given without an interval
DRAFT-AOD-9604-MON/008	Draft monograph: AOD-9604	Dr Odalys Thorsby-Nakamura	The preclinical section is extensive and the clinical section is not
DRAFT-AOD-9604-MON/007	Draft monograph: AOD-9604	Sigrún Vercingetorix	Anti-drug antibody data are omitted
DRAFT-AOD-9604-MON/004	Draft monograph: AOD-9604	Dr Gaspard Wintringham	Storage and reconstitution guidance is given without stating what it rests on
DRAFT-AOD-9604-MON/003	Draft monograph: AOD-9604	Dr Oisín Rautavaara industry	The monograph should reproduce the approved labelling rather than paraphrase it
DRAFT-CAGRILINTIDE/001	Draft monograph: Cagrilintide	Dr Séverin Oppenheimer-Ade	The analytical section is longer than the clinical assessment it accompanies

page 5 of 13